[논문]A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain

Jansen, Jan-Peter; Lorch, Daniel; Langan, John; Lasko, Ben; Hermanns, Kai; Kleoudis, Christi S.; Snidow, Jerry W.; Pierce, Amy; Wurzelmann, John; Mortensen, Eric R.

doi:10.1016/j.jpain.2010.06.012

A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain 원문보기

The journal of pain : official journal of the American Pain Society, v.12 no.2, 2011년, pp.185 - 193

Jansen, Jan-Peter (SZ Pain Center Berlin, Berlin, Germany) , Lorch, Daniel (Brandon Regional Hospital, Brandon, Florida) , Langan, John (Baillieston Health Centre, Glasgow, United Kingdom) , Lasko, Ben (Manna Research, Toronto, Canada) , Hermanns, Kai (Center of Pain Therapy Berlin, Prenzlauer Berg, Berlin, Germany) , Kleoudis, Christi S. (GlaxoSmithKline, Research Triangle Park, North Carolina) , Snidow, Jerry W. (GlaxoSmithKline, Research Triangle Park, North Carolina) , Pierce, Amy (GlaxoSmithKline, Research Triangle Park, North Carolina) , Wurzelmann, John (GlaxoSmithKline, Research Triangle Park, North Carolina) , Mortensen, Eric R. (GlaxoSmithKline, Research Triangle Park, North Carolina)

Abstract ▼ AI-Helper

AbstractGastrointestinal (GI) side effects are common with opioid medication, and constipation affects ∼40% of patients. Such symptoms considerably impair patients' quality of life. Alvimopan is an orally administered, systemically available, peripherally acting mu-opioid receptor (PAM-OR) antagonist approved in the US for short-term, in-hospital management of postoperative ileus in patients undergoing bowel resection. This double-blind, placebo-controlled trial was conducted as part of a recently discontinued clinical program, in which alvimopan was being developed for opioid-induced constipation (OIC). Patients (N = 518) receiving opioids for non-cancer pain were randomized to receive alvimopan .5 mg once daily, alvimopan .5 mg twice daily, or placebo for 12 weeks. The primary efficacy endpoint was the proportion of patients experiencing ≥3 spontaneous bowel movements (SBMs; bowel movements with no laxative use in the previous 24 hours) per week over the treatment period and an average increase from baseline of ≥1 SBM per week. A significantly greater proportion of patients in the alvimopan .5 mg twice-daily group met the primary endpoint compared with placebo (72% versus 48%, P < .001). Treatment with alvimopan twice daily improved a number of other symptoms compared with placebo and reduced the requirement for rescue laxative use. The opioid-induced bowel dysfunction Symptoms Improvement Scale (SIS) responder rate was 40.4% in the alvimopan .5 mg twice daily group, versus 18.6% with placebo (P < .001). In general, alvimopan .5 mg once daily produced qualitatively similar but numerically smaller responses than twice-daily treatment. Active treatment did not increase the requirement for opioid medication or increase average pain intensity scores. Over the 12-week treatment period, alvimopan appeared to be well tolerated.PerspectiveThese results demonstrate the potential for a PAM-OR antagonist to improve the symptoms of OIC without antagonizing opioid analgesia.

주제어

참고문헌 (24)

Adolor Provides Update on Entereg® (alvimopan) OBD Program. Adolor press release. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p=irol-newsArticle&ID=1171802&highlight= Accessed February 26, 2010
Adolor Corporation: Adolor Corporation opioid bowel dysfunction development program. Available at: http://www.adolor.com/research/index.asp?page=obd-clinical-development-program Accessed March 17, 2010
Adolor Corporation: Entereg® (alvimopan) capsules for postoperative ileus (POI). Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4336b1-02-Adolor.pdf Accessed March 15, 2010
Adolor Corporation: Prescribing information for Entereg (alvimopan). Available at: http://www.entereg.com/pdf/prescribing-information.pdf Accessed March 16, 2010
BMJ Allan 322 1154 2001 10.1136/bmj.322.7295.1154 Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain

상세보기
Curr Opin Investig Drugs Azodo 3 1496 2002 Alvimopan (Adolor/GlaxoSmithKline)

상세보기
Neurogastroenterol Motil Camilleri 17 157 2005 10.1111/j.1365-2982.2005.00640.x Alvimopan, a selective peripherally acting mu-opioid antagonist

상세보기
Pharmacol Ther De Luca 69 103 1996 10.1016/0163-7258(95)02053-5 Insights into opioid action in the intestinal tract

상세보기
Pharmacol Ther DeHaven-Hudkins 117 162 2008 10.1016/j.pharmthera.2007.09.007 The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: Therapeutic opportunities for antagonism at this receptor

상세보기
Clin Gastroenterol Hepatol Gonenne 3 784 2005 10.1016/S1542-3565(05)00434-9 Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study

상세보기
Jaffe 1990 The Pharmacological Basis of Therapeutics Opioid Analgesics and Antagonists
Pain Kalso 112 372 2004 10.1016/j.pain.2004.09.019 Opioids in chronic non-cancer pain: Systematic review of efficacy and safety

상세보기
Gastroenterology Kaufman 94 1351 1988 10.1016/0016-5085(88)90673-7 Role of opiate receptors in the regulation of colonic transit

상세보기
Drugs Kurz 63 649 2003 10.2165/00003495-200363070-00003 Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

상세보기
Lennard-Jones 181 2002 Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management Constipation
Support Care Cancer Mancini 6 356 1998 10.1007/s005200050177 Constipation in advanced cancer patients

상세보기
J Pain McNicol 4 231 2003 10.1016/S1526-5900(03)00556-X Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review

상세보기
National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Adult cancer pain, v.1.2009 [published 4/16/09]. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed March 8, 2010
Am J Surg Pappagallo 182 5A Suppl 11S 2001 10.1016/S0002-9610(01)00782-6 Incidence, prevalence, and management of opioid bowel dysfunction

상세보기
J Pain Paulson 6 184 2005 10.1016/j.jpain.2004.12.001 Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial

상세보기
Curr Pain Headache Rep Thorpe 5 237 2001 10.1007/s11916-001-0037-7 Management of opioid-induced constipation

상세보기
J Pain Symptom Manage Walsh 5 362 1990 10.1016/0885-3924(90)90031-E Prevention of opioid side effects

상세보기
Pain Webster 137 428 2008 10.1016/j.pain.2007.11.008

상세보기
Wyeth Pharmaceuticals Inc: Prescribing information for Relistor (methylnaltrexone bromide). Available at: http://www.wyeth.com/content/showlabeling.asp?id=499 Accessed March 16, 2010

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (24)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트